Comparison of clinical traits for seasonal and perennial allergic rhinitis during allergen exposure

医学 鼻漏 优势比 置信区间 过敏原 过敏性结膜炎 鼻塞 内科学 过敏 皮肤病科 哮喘 免疫学 外科 鼻子
作者
Kunpeng Wang,Yuan Zhang,Lianqi Wan,Jingyun Li,Chengshuo Wang,Luo Zhang
出处
期刊:Allergy and Asthma Proceedings [OceanSide Publications, Inc]
卷期号:45 (3): 173-179 被引量:4
标识
DOI:10.2500/aap.2024.45.240009
摘要

Background: Allergic rhinitis (AR) is traditionally subdivided into seasonal AR (SAR) and perennial AR (PAR) according to the type of allergen and the occurrence of symptoms during the year. There are currently no reports on the comparison of trait profiles for SAR and PAR during the allergen exposure. Purpose: The purpose of this study was to analyze the clinical characteristics of SAR and PAR during respective allergen exposure periods to provide valuable information for the development of treatment strategies. Methods: This study was performed between August 1, 2021, and January 31, 2022, in the Department of Allergy, Beijing Tongren Hospital. We continuously included diagnosed SAR and PAR outpatients who volunteered to participate in the survey. A questionnaire with regard to medical history, severity of symptoms, and diagnosis and treatment status was collected. Results: A total of 296 patients with SAR and 448 with PAR were finally recruited. Patients with SAR had more severe rhinorrhea compared with patients with PAR (p < 0.001), whereas there was no statistically significant difference in the severity of itching, sneezing, and congestion between the two entities (p ≥ 0.05). Both the gritty and watery eyes of patients with SAR were noticeably more severe than those of patients with PAR (PTotal Ocular Symptom Score [PTOSS] < 0.001). AR symptom severity is mainly associated with the comorbid allergic conjunctivitis (odds ratio 1.94 [95% confidence interval, 1.21-3.09]). SAR patients and PAR patients show no statistically significant differences in terms of their frequency of visits, annual expenditure, and choice of medication treatment for AR (p > 0.05). The overall control under standard medication of both patients with PAR and those with SAR is not ideal, especially in SAR. Conclusion: The current cross-sectional study demonstrated that the patients with SAR exhibited more severe overall clinical symptoms than those with PAR, especially nasal rhinorrhea and gritty and watery eyes. Both of the two disease entities have poor control under standardized medication treatment, especially in SAR. Further multicenter longitudinal studies that involve larger and more diverse populations should be conducted to provide a more accurate and comprehensive understanding of the condition.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
俭朴听南完成签到,获得积分10
1秒前
1秒前
1秒前
桐桐应助Morin采纳,获得10
2秒前
美满平松完成签到 ,获得积分10
2秒前
Jasper应助pansy采纳,获得30
2秒前
Jasper应助fishss采纳,获得10
4秒前
5秒前
余铸海发布了新的文献求助10
5秒前
5秒前
lcz发布了新的文献求助10
6秒前
星辰大海应助zjq采纳,获得10
6秒前
ghdltkdtn56完成签到,获得积分10
6秒前
SciGPT应助TYT采纳,获得10
7秒前
TYH_235发布了新的文献求助10
8秒前
9秒前
dddddw完成签到,获得积分10
10秒前
充电宝应助赵伟豪采纳,获得10
10秒前
Lee_Peng发布了新的文献求助10
11秒前
11秒前
汤圆完成签到,获得积分10
11秒前
12秒前
lailight完成签到,获得积分10
13秒前
cz发布了新的文献求助10
14秒前
14秒前
Lucas应助waker采纳,获得10
15秒前
15秒前
落后猕猴桃完成签到,获得积分10
16秒前
难过龙猫完成签到,获得积分10
17秒前
17秒前
17秒前
19秒前
可爱的函函应助老杨采纳,获得10
19秒前
科研通AI6.2应助小豆芽芽采纳,获得10
20秒前
20秒前
无极微光应助难过龙猫采纳,获得20
20秒前
小龙完成签到,获得积分10
20秒前
赵伟豪发布了新的文献求助10
20秒前
小西贝完成签到 ,获得积分10
22秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
PowerCascade: A Synthetic Dataset for Cascading Failure Analysis in Power Systems 2000
Picture this! Including first nations fiction picture books in school library collections 1500
Signals, Systems, and Signal Processing 610
Unlocking Chemical Thinking: Reimagining Chemistry Teaching and Learning 555
CLSI M100 Performance Standards for Antimicrobial Susceptibility Testing 36th edition 400
Cancer Targets: Novel Therapies and Emerging Research Directions (Part 1) 400
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 工程类 有机化学 化学工程 生物化学 计算机科学 物理 内科学 复合材料 催化作用 物理化学 光电子学 电极 细胞生物学 基因 无机化学
热门帖子
关注 科研通微信公众号,转发送积分 6361439
求助须知:如何正确求助?哪些是违规求助? 8175188
关于积分的说明 17221423
捐赠科研通 5416250
什么是DOI,文献DOI怎么找? 2866218
邀请新用户注册赠送积分活动 1843512
关于科研通互助平台的介绍 1691443